Shares in BARD1 Life Sciences have more than doubled, after the diagnostics business revealed its SubB2M technology can be used to detect all stages of breast cancer.
Cancer-focused medical technology company BARD1 Life Sciences has raised around $7.5 million via a share placement and rights issue, and has appointed two non-executive directors to its board.
